Antiphospholipid syndrome

What is Antiphospholipid syndrome?

Antiphospholipid syndrome (APS), also known as Hughes syndrome, is an autoimmune disorder where the body’s immune system mistakenly produces antibodies that target phospholipid-binding proteins, leading to an increased risk of blood clots. This condition affects approximately 40-50 people per 100,000 population, making it a relatively rare but serious autoimmune disease. APS can occur at any age but most commonly affects adults between 20-50 years old, with women being affected more frequently than men, particularly during their reproductive years. The condition is characterized by recurrent blood clots in arteries and veins, pregnancy complications including recurrent miscarriages, and the presence of specific antiphospholipid antibodies in the blood.

Key statistics

Symptoms

Blood clots in veins and arteries, recurrent miscarriages, livedo reticularis (lace-like skin discoloration), thrombocytopenia (low platelet count), neurological symptoms, heart valve abnormalities.

The symptoms of APS vary widely depending on where blood clots form in the body. Vascular symptoms include deep vein thrombosis (typically in legs), pulmonary embolism (blood clots in lungs), and arterial clots that can cause stroke or heart attack. Pregnancy-related symptoms encompass recurrent miscarriages (especially after 10 weeks of pregnancy), stillbirth, severe preeclampsia, and intrauterine growth restriction. Skin manifestations include livedo reticularis, a distinctive purple, lace-like skin discoloration most visible on arms and legs, as well as skin ulcers and digital gangrene in severe cases. Neurological symptoms may include headaches, seizures, memory problems, and in severe cases, stroke or transient ischemic attacks. Hematological features often involve thrombocytopenia (low platelet count) and hemolytic anemia. Some patients develop cardiac complications including heart valve thickening or vegetation (Libman-Sacks endocarditis).

Causes and risk factors

APS is an autoimmune condition where the immune system produces antibodies against phospholipid-binding proteins, particularly beta-2 glycoprotein I and prothrombin. The exact trigger for this autoimmune response remains unknown, but both genetic and environmental factors likely contribute. While APS is not directly inherited, there may be a genetic predisposition to developing autoimmune conditions. Environmental triggers may include infections (particularly with certain bacteria and viruses), medications, and other autoimmune diseases. Risk factors include female gender, having other autoimmune conditions (especially systemic lupus erythematosus), family history of autoimmune diseases, and certain genetic variants in immune system genes. Primary APS occurs alone, while secondary APS occurs alongside other autoimmune conditions, most commonly lupus.

Submit Your Paper

Prevention

There is no known way to prevent the development of APS since it is an autoimmune condition with unclear environmental triggers. However, once diagnosed, preventive measures focus on reducing the risk of blood clots and pregnancy complications. Individuals with known APS antibodies but no history of clotting events may benefit from low-dose aspirin, particularly during high-risk periods such as surgery, prolonged immobilization, or pregnancy. Lifestyle modifications including regular exercise, maintaining healthy weight, avoiding smoking, and staying hydrated can help reduce clotting risk. For family members, genetic counseling may be beneficial to understand the slightly increased risk of developing autoimmune conditions, though routine screening is not recommended unless symptoms develop.

Complications

Without proper treatment, APS can lead to severe, life-threatening complications. Recurrent blood clots can cause permanent organ damage, including chronic kidney disease from renal artery thrombosis, pulmonary hypertension from recurrent pulmonary embolisms, and cognitive impairment from multiple small strokes. Catastrophic antiphospholipid syndrome (CAPS) is a rare but potentially fatal complication involving widespread clotting affecting multiple organs simultaneously. Pregnancy complications include not only recurrent pregnancy loss but also severe maternal complications such as HELLP syndrome (hemolysis, elevated liver enzymes, low platelets) and life-threatening preeclampsia. Long-term complications may include post-thrombotic syndrome with chronic pain and swelling in affected limbs, and increased cardiovascular disease risk due to arterial damage from recurrent clots.

Diagnosis

Diagnosing APS requires both clinical criteria and laboratory evidence. The clinical criteria include vascular thrombosis (one or more episodes of arterial, venous, or small vessel thrombosis) and/or pregnancy morbidity (recurrent early pregnancy loss, late pregnancy loss, or severe preeclampsia). Laboratory criteria require positive antiphospholipid antibodies on two or more occasions at least 12 weeks apart. The three main antibody tests are: anticardiolipin antibodies (IgG and/or IgM), anti-beta-2 glycoprotein I antibodies (IgG and/or IgM), and lupus anticoagulant. Additional testing may include complete blood count to check for thrombocytopenia, comprehensive metabolic panel to assess organ function, and imaging studies such as ultrasound, CT, or MRI to identify blood clots. Some patients may undergo echocardiography to evaluate heart valves. The diagnosis can be challenging as antibody levels may fluctuate, and other conditions must be ruled out.

Treatment

Treatment focuses on preventing blood clots and managing complications. For patients with confirmed thrombotic events, long-term anticoagulation is the standard treatment. Warfarin has been the traditional first-line therapy, with target INR (international normalized ratio) typically maintained between 2.0-3.0, though some patients may require higher targets. Heparin (both unfractionated and low molecular weight heparin) is used during pregnancy, acute thrombotic events, and when bridging to oral anticoagulants. Low-dose aspirin (75-100mg daily) is often used for primary prevention in antibody-positive patients without thrombosis history, and as adjunctive therapy with anticoagulants. Direct oral anticoagulants (DOACs) are being studied but remain controversial in APS, with warfarin still preferred for most patients. Additional treatments may include hydroxychloroquine for patients with concurrent lupus, immunosuppressive medications in refractory cases, and plasma exchange for catastrophic APS. Supportive care addresses specific complications such as antihypertensive medications for kidney involvement.

Prognosis

With appropriate anticoagulant treatment, the prognosis for APS has improved significantly. Most patients can achieve good thrombosis prevention with proper anticoagulation, though they require lifelong treatment and monitoring. The 10-year survival rate exceeds 90% for patients receiving appropriate therapy. However, prognosis varies considerably based on the pattern and severity of initial manifestations. Patients with arterial thrombosis, particularly stroke, may have more serious long-term complications compared to those with only venous clots. Pregnancy outcomes have dramatically improved with modern treatment protocols, with live birth rates of 70-80% achievable in many cases. The main challenges include balancing anticoagulation benefits with bleeding risks, managing complications during pregnancy, and preventing rare but serious events like catastrophic APS. Quality of life can be good with proper management, though some patients experience chronic symptoms requiring ongoing medical care.

Quality of life

Living with APS requires ongoing medical management but many patients maintain active, fulfilling lives. Daily anticoagulation management becomes routine, though patients must remain vigilant about bleeding risks and drug interactions. Regular exercise is encouraged as it helps prevent blood clots, but contact sports and activities with high injury risk should be avoided. Diet considerations include maintaining consistent vitamin K intake if taking warfarin, staying well-hydrated, and limiting alcohol consumption. Mental health support is important as the chronic nature of the condition and pregnancy complications can cause anxiety and depression. Many patients benefit from connecting with support groups and patient organizations. Work and school accommodations may be needed during acute episodes or for frequent medical appointments. Travel requires special planning including compression stockings, frequent movement, and coordination with healthcare providers for anticoagulation management. Patients should wear medical alert identification and maintain emergency medication supplies.

Pregnancy and fertility

APS significantly impacts pregnancy but successful outcomes are achievable with specialized care. Women with APS require preconception counseling and high-risk obstetric management throughout pregnancy. Fertility may be reduced due to recurrent pregnancy loss, but the underlying fertility potential is typically normal. During pregnancy, anticoagulation switches from warfarin to low molecular weight heparin combined with low-dose aspirin. Close monitoring includes frequent blood tests, regular ultrasounds to assess fetal growth, and screening for preeclampsia. Delivery planning involves coordinating anticoagulation management with obstetric and anesthetic teams. Breastfeeding is generally safe with appropriate anticoagulant choices. Postpartum anticoagulation is crucial as this period carries high thrombosis risk. Contraceptive counseling is important as estrogen-containing methods may increase clotting risk. Genetic counseling helps families understand that while APS itself is not directly inherited, there may be slightly increased autoimmune disease risk in offspring.

Children

Pediatric APS is rare but can occur, most commonly in adolescents. Children may develop APS secondary to other autoimmune conditions or infections. Diagnosis follows similar criteria to adults but requires careful consideration of normal developmental variations in coagulation systems. Treatment principles are similar but dosing and monitoring require pediatric expertise. Special considerations include impact on growth and development, school attendance, activity restrictions, and psychosocial support. Children born to mothers with APS may rarely develop neonatal complications due to transplacental antibody transfer, but this typically resolves as maternal antibodies clear from the infant’s system. Long-term follow-up is important as some children may develop other autoimmune conditions over time. Family education focuses on recognizing symptoms of blood clots and managing anticoagulation safely in the home environment.

When to see a doctor

Urgent medical attention is needed for symptoms suggesting blood clots: sudden leg swelling or pain, chest pain or shortness of breath, sudden severe headache, vision changes, weakness or numbness on one side of the body, or sudden speech difficulties. During pregnancy, immediate evaluation is required for severe headaches, visual disturbances, severe abdominal pain, or decreased fetal movement. Routine medical care should address recurrent miscarriages (typically after two or more losses), unexplained blood clots at any age (especially under 50), family history of early stroke or heart attack, or persistent unusual skin discoloration. Patients with known APS should maintain regular follow-up for anticoagulation monitoring and should contact their healthcare provider for signs of bleeding, medication interactions, or planned procedures requiring anticoagulation adjustment. Annual comprehensive evaluations help monitor for complications and adjust treatment as needed.

Regional context

Limited specific data exists for APS prevalence in the Caucasus region (Georgia, Armenia, Azerbaijan) and Eastern Mediterranean countries. However, the condition likely occurs at similar rates to global prevalence estimates. Some studies suggest autoimmune diseases may have varying prevalence across different ethnic populations, potentially influenced by genetic factors and environmental triggers. Regional healthcare challenges may include access to specialized rheumatology or hematology care, availability of consistent anticoagulation monitoring, and patient education resources in local languages. Healthcare providers in these regions are encouraged to contribute data and clinical experiences to the Global Medical Journal to improve understanding of APS patterns and outcomes in diverse populations. Collaboration with international APS registries and research networks could enhance regional expertise and patient care standards.

Research and clinical trials

Current APS research focuses on understanding disease mechanisms, improving treatment strategies, and developing new therapies. Active areas include investigating the role of complement activation, exploring new anticoagulant options including direct oral anticoagulants, and developing targeted immunomodulatory therapies. Recent studies examine the use of hydroxychloroquine for thrombosis prevention and rituximab for refractory cases. Pregnancy-related research investigates optimal anticoagulation protocols and novel treatments for recurrent pregnancy loss. Biomarker research aims to identify patients at highest risk for thrombotic events. Clinical trials are evaluating new therapeutic targets including complement inhibitors and specific antibody-neutralizing agents. Patients can search for relevant clinical trials at ClinicalTrials.gov using terms like “antiphospholipid syndrome,” “APS,” or “Hughes syndrome.” Participation in research registries helps advance understanding of long-term outcomes and treatment effectiveness. International collaborative studies continue to refine diagnostic criteria and treatment guidelines.

Frequently asked questions

Is APS the same as having “thick blood”?

No, APS is not about blood thickness but rather an autoimmune condition where antibodies interfere with normal blood clotting regulation, leading to inappropriate clot formation in blood vessels.

Will I need to take blood thinners for life?

Most patients with APS who have had thrombotic events require long-term anticoagulation, though the specific medication and intensity may be adjusted based on individual risk factors and response to treatment.

Can I have a normal pregnancy with APS?

Yes, with proper medical management including specialized anticoagulation protocols and high-risk obstetric care, many women with APS can achieve successful pregnancies and healthy babies.

Does having antiphospholipid antibodies mean I have APS?

Not necessarily. Some people have positive antibodies without clinical symptoms. APS diagnosis requires both positive antibodies (confirmed on repeat testing) and clinical evidence of blood clots or pregnancy complications.

Are there dietary restrictions with APS treatment?

If taking warfarin, you should maintain consistent vitamin K intake but don’t need to avoid vitamin K-rich foods entirely. With other anticoagulants, there are typically fewer dietary restrictions, but always consult your healthcare provider.

Support and resources

APS Foundation of America
Website: apsfa.org
Provides patient education, support networks, and research funding for antiphospholipid syndrome.

Hughes Syndrome Foundation
Website: hughes-syndrome.org
UK-based organization offering information and support for patients with APS/Hughes syndrome worldwide.

Lupus Foundation of America
Website: lupus.org
Provides resources for APS patients, particularly those with secondary APS associated with lupus.

National Organization for Rare Disorders (NORD)
Website: rarediseases.org
Comprehensive information about rare diseases including APS, with patient advocacy and support resources.

Orphanet
Website: orpha.net
European database of rare diseases providing detailed medical and practical information about APS.

Related conditions

Systemic lupus erythematosus
Thrombotic thrombocytopenic purpura
Factor V Leiden
Protein C deficiency
Catastrophic antiphospholipid syndrome

Sources: Orphanet (orpha.net), OMIM, GeneReviews (NCBI), WHO ICD-11, relevant guidelines. Informational only; not medical advice. CC BY 4.0.

Licensed under CC BY 4.0. Free to share with attribution to GMJ News.

Sources: Orphanet (orpha.net), OMIM, GeneReviews (NCBI), WHO ICD-11, EULAR/ACR guidelines. Schema.org MedicalCondition structured data included.